Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclomethyltryptophan SCHEMBL7889282 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL416557 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL29535380 | 1.00 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL10642614 | 0.98 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL28419799 | 0.98 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12257169 | 0.90 | CYP2D6 (0.58) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10639172 | 0.87 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1877421 | 0.87 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3110230 | 0.87 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13840607 | 0.87 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436005-B1 | L-1,2,3,4-TETRAHYDRONORHARMAN-3-CARBOXYLIC ACID (TNCA) FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MUTATED OR ABNORMAL CALCIUM SENSING RECEPTOR PROTEIN (CASR) | UNIV GEORGIA STATE RES FOUND (US) | 2026-01-28 | — | — | EP | claimed |
| CN-118267409-A | Preparation method of passion fruit seed extract and application of passion fruit seed extract in preparation of composition for improving sleep quality | 大江生医股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| CN-118091005-A | Method for detecting multiple components in deer astragalus kidney-tonifying particles | 上海市第七人民医院(上海中医药大学附属第七人民医院) | 2024-05-28 | — | — | CN | claimed |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2024-03-14 | — | — | US | claimed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | claimed |
| WO-2000074702-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2000-12-14 | — | — | WO | claimed |
| EP-0736039-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2000-10-25 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| EP-0891187-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-20 | — | — | EP | claimed |
| US-5767085-A | PEPTIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-06-16 | — | — | US | claimed |
| EP-0833845-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-04-08 | — | — | EP | claimed |
| WO-1997037658-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1997-10-16 | — | — | WO | claimed |
| WO-1997000894-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-01-09 | — | — | WO | claimed |
| EP-0736039-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | claimed |
| WO-1995017423-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | KDM4E 1553/4885CYP2D6 204/4885CYP1A2 90/4885 |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | KDM4E 4852/4885CYP2D6 4791/4885CYP1A2 4872/4885 |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | KDM4E 4844/4885CYP2D6 3191/4885CYP1A2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.